CPT® Code 83992

1. Indications

The test coded as CPT® 83992 is indicated for the assessment of phencyclidine (PCP) levels in various clinical scenarios. The following conditions or situations may warrant this testing:

• Substance Abuse Evaluation Testing may be performed when there is a suspicion of PCP use or abuse, particularly in individuals presenting with altered mental status or unusual behavior.
• Newborn Assessment Meconium testing is indicated for newborns to determine potential exposure to PCP during pregnancy, which can have implications for the infant's health and development.
• Monitoring Treatment The test may be utilized to monitor patients undergoing treatment for substance use disorders, ensuring compliance and assessing the effectiveness of interventions.

2. Procedure

The procedure for testing phencyclidine (PCP) levels involves several key steps, each critical for obtaining accurate results. The first step is the collection of the appropriate specimen. For blood testing, a healthcare professional performs venipuncture to draw a blood sample from the patient. This procedure must be reported separately, as it is not included in the CPT® code for the PCP test itself. In cases where urine testing is required, a random void specimen is collected from the patient, which is a straightforward process that involves the patient urinating into a sterile container. For newborns, meconium stool is collected from the diaper, which is the first stool passed by an infant and can provide valuable information regarding in utero drug exposure. Once the specimens are collected, they are subjected to quantitative gas chromatography-mass spectrometry, a highly sensitive and specific analytical method that separates and quantifies the PCP present in the samples. This method ensures that the results are reliable and can be used for clinical decision-making.

3. Post-Procedure

After the procedure, there are no specific post-procedure care requirements directly associated with the PCP testing itself. However, it is essential for healthcare providers to interpret the results in the context of the patient's clinical history and presentation. If the test indicates the presence of PCP, further evaluation and management may be necessary, particularly in cases of suspected substance abuse or in newborns who may require additional monitoring and support. Providers should also ensure that patients are informed about the test results and any subsequent steps that may be needed based on those results.